Skip to main content

Table 2 Total number of consultations provided by general practitioners per population

From: A mixed-method study on the provision of remote consultations for non-communicable disease patients during the first wave of the COVID-19 pandemic in Latvia: lessons for the future

 

No. of consultations per 100,000 populationa per day (95% CI)

2019

2020

Difference between 2020 and 2019, p-value

Difference within 2020, p-value

C50

 Period I-III

4.69 (4.57; 4.80)

4.87 (4.76; 4.99)

0.18 (0.02; 0.35), 0.025

 

 Period I

4.81 (4.63; 4.99)

5.12 (4.94; 5.31)

0.32 (0.06; 0.57), 0.014

 Period II

4.49 (4.30; 4.69)

4.12 (3.93; 4.30)

−0.38 (− 0.64; − 0.11), 0.005

 Period III

4.75 (4.52; 4.98)

5.46 (5.22; 5.71)

0.71 (0.38; 1.04), < 0.001

  Period II vs Period I

   

−1.01 (−1.27; −0.75), < 0.001

  Period III vs Period II

1.34 (1.04; 1.65), < 0.001

  Period III vs Period I

0.33 (0.03; 0.64), 0.031

C61

 Period I-III

5.18 (5.05; 5.31)

5.39 (5.26; 5.53)

0.22 (0.03; 0.41), 0.022

 

 Period I

5.39 (5.19; 5.61)

5.95 (5.73; 6.17)

0.55 (0.25; 0.85), < 0.001

 Period II

4.97 (4.75; 5.19)

4.24 (4.03; 4.45)

−0.73 (− 1.03; − 0.43), < 0.001

 Period III

5.09 (4.83; 5.36)

6.02 (5.74; 6.31)

0.93 (0.54; 1.31), < 0.001

  Period II vs Period I

   

−1.71 (−2.01; − 1.41), < 0.001

  Period III vs Period II

1.78 (1.43; 2.13), < 0.001

  Period III vs Period I

0.07 (−0.29; 0.43), 0.703

E10, E11

 Period I-III

19.67 (19.49; 19.84)

19.35 (19.18; 19.52)

−0.32 (− 0.56; − 0.08), 0.010

 

 Period I

20.42 (20.15; 20.69)

20.82 (20.55; 21.09)

0.40 (0.02; 0.79), 0.040

 Period II

18.64 (18.35; 18.93)

15.82 (15.56; 16.09)

−2.82 (−3.21; − 2.42), < 0.001

 Period III

19.78 (19.44; 20.13)

21.59 (21.23; 21.95)

1.81 (1.31; 2.31), < 0.001

  Period II vs Period I

   

−4.99 (−5.37; − 4.61), < 0.001

  Period III vs Period II

5.77 (5.32; 6.21), < 0.001

  Period III vs Period I

0.77 (0.32; 1.22), < 0.001

I10, I20-I25, I50

 Period I-III

135.64 (135.20; 136.10)

142.79 (142.30; 143.30)

7.16 (6.51; 7.80), < 0.001

 

 Period I

140.63 (139.90; 141.30)

149.77 (149.00; 150.50)

9.15 (8.13; 10.16), < 0.001

 Period II

130.17 (129.40; 130.90)

121.27 (120.50; 122.00)

−8.90 (−9.96; −7.84), < 0.001

 Period III

134.62 (133.70; 135.50)

159.86 (158.90; 160.80)

25.24 (23.92; 26.57), < 0.001

  Period II vs Period I

   

− 28.50 (−29.54; −27.46), < 0.001

  Period III vs Period II

38.59 (37.36; 39.81), < 0.001

  Period III vs Period I

10.09 (8.87; 11.31), < 0.001

J44, J45

 Period I-III

10.06 (9.94; 10.18)

10.62 (10.50; 10.75)

0.56 (0.39; 0.74), < 0.001

 

 Period I

10.71 (10.52; 10.91)

10.63 (10.44; 10.83)

−0.08 (− 0.36; 0.19), 0.557

 Period II

9.70 (9.49; 9.91)

10.70 (10.48; 10.92)

1.00 (0.70; 1.31), < 0.001

 Period III

9.46 (9.22; 9.70)

10.50 (10.25; 10.76)

1.04 (0.70; 1.39), < 0.001

  Period II vs Period I

   

0.07 (−0.22; 0.36), 0.648

  Period III vs Period II

−0.20 (− 0.53; 0.14), 0.246

  Period III vs Period I

−0.13 (− 0.45; 0.19), 0.428

  1. a Female and male populations for breast and prostate cancer consultations, respectively